Walmart Just Proved It: A GLP-1 Might Be the Best Financial Decision You Make This Year

She's staring at the SkinnyVIP pricing page. $220/month, month-to-month. Another bill. Another line item. She hovers over the consultation button and hesitates.

Here's the question she isn't asking: what if a GLP-1 doesn't just cost $220 a month — what if it also reduces what she's already spending? What if the medication changes her relationship with food, alcohol, and restaurants in ways that partially or fully offset its own cost?

This is a pattern that three of the world's most sophisticated consumer data companies have reported independently — Walmart, Nestle, and Morgan Stanley. None had any reason to say this. In fact, two had strong reasons not to. But the data kept showing up in earnings calls and analyst reports.

Important upfront: This is not financial advice. Individual results vary significantly. Many patients on GLP-1 medications report no meaningful change in their spending. Some spend more. The goal of this article is to challenge the assumption that a GLP-1 is purely additive to your budget — not to promise savings. The pattern in the data deserves a serious look.

Walmart's CEO Said The Quiet Part Out Loud

In October 2023, Walmart CEO Doug McMillon told Bloomberg that Walmart was observing customers using GLP-1 medications buying measurably less food — detectable in Walmart's purchase data across a large customer base.

This matters because Walmart is not working from surveys — they have actual purchase data. When Walmart says customers on GLP-1s are buying less food, they mean that transaction-level receipts show smaller food baskets from that customer segment. Read the original Bloomberg report here.

McMillon was careful, framing it as "slight" and early-stage. But the fact that it registered at all — at a scale large enough to be reportable — is telling. Many patients report their grocery basket gets smaller and restaurant visits decrease. Walmart's data suggests this pattern is measurable at population scale.

Individual results may vary. Not all patients on GLP-1 medications experience reduced food spending.

Nestle Felt It In Their Stock Price

In early 2024, Nestle CEO Mark Schneider addressed GLP-1s directly in comments reported by Reuters: GLP-1 medications were being cited as a meaningful factor in the company's strategic planning around packaged food sales. Read Reuters' coverage of Nestle's GLP-1 comments here.

Nestle's stock dropped notably in 2023–2024 as investors began pricing in the long-term implications of widespread GLP-1 adoption. The company restructured its product portfolio toward lower-calorie, higher-protein options in direct response to the behavioral changes GLP-1 users were showing in the market.

What does it take for the CEO of a $250 billion food company to publicly acknowledge that a medication is reducing his customers' appetite for his products? A lot. Nestle has no incentive to promote GLP-1s. When their CEO says GLP-1s are affecting packaged food consumption, he's saying it because investors required honest reporting — not because it helps him.

Morgan Stanley Ran the Numbers

In 2023, Morgan Stanley's research team surveyed patients actively using GLP-1 medications and tracked their self-reported spending behavior changes. The results were striking enough to be published as a featured market research piece — because the investment implications for food, beverage, restaurant, and retail companies were substantial. Read the Morgan Stanley GLP-1 market analysis here.

Among the behavioral changes that GLP-1 users reported:

• Eating out at restaurants less frequently — fewer visits per month and smaller orders when they did go
• Smaller grocery baskets — particularly in snack foods, processed foods, and impulse-buy categories
• Reduced alcohol purchases — a finding that has since been replicated in clinical research (more on this below)
• Decreased spending on sugary beverages, candy, and snack categories specifically

Morgan Stanley framed this as a significant concern for publicly traded food and beverage companies — a signal that high GLP-1 adoption could structurally reduce spending in these categories over time.

The Math Most People Don't Do

According to Bureau of Labor Statistics Consumer Expenditure data, the average U.S. household spends approximately:

• $450–$500/month on food at home (groceries)
• $340/month on food away from home (restaurants, takeout, delivery)
• $60–$80/month on alcoholic beverages

That's roughly $850–$920/month in food and beverage spending for a typical household, before accounting for snacks, coffee runs, and convenience purchases. Now consider what a hypothetical patient — not you, not a promise, just an illustrative example — might experience if their eating patterns shift on a GLP-1:

In this illustrative scenario, a patient who reduces food and alcohol spending by $150–$300/month on a $220/month medication is approaching cost-neutral — or better. That's a very different mental calculation than "I can't afford another $220 bill."

The Alcohol Line Item Is the Biggest Surprise

Of all the spending categories in the table above, the alcohol line surprises patients most. Many people start a GLP-1 expecting changes in food appetite — fewer cravings, smaller portions. But reduced interest in alcohol is not something most patients anticipate, and it may represent the most significant single-line-item reduction for patients who drink regularly.

A 2024 study published in JAMA Psychiatry found that GLP-1 receptor agonists were associated with significant reductions in alcohol cravings and consumption among participants. The researchers observed that the same neurological pathways that GLP-1 medications affect for appetite regulation also appear to be involved in reward-seeking behaviors — including the desire to drink.

Important compliance note: GLP-1 medications are not FDA-approved for alcohol use disorder. This is emerging research, not an approved indication. Patients should not start a GLP-1 specifically as an alcohol intervention without discussing this with their physician. We're covering the clinical data on this in more depth separately — see our upcoming deep dive on GLP-1s and alcohol cravings.

That said, for patients who drink moderately to regularly, many patients report that their interest in alcohol decreases meaningfully on a GLP-1. If that shift happens for you, that's a real and sometimes surprising reduction in a line item that many households hadn't thought to count.

What Doesn't Change

Not everyone who starts a GLP-1 will experience reduced food spending. The population-level data from Walmart, Morgan Stanley, and consumer research firms is a trend — not a prediction for any individual patient.

Here's what many patients actually experience that doesn't reduce spending, or may increase it:

• Shifting to higher-quality foods. Many patients on GLP-1s trade volume for quality — buying better produce, higher-protein foods, or organic options that cost more per unit. Net grocery bill: roughly the same or slightly higher, with better nutrition.
• New wardrobe spending. Patients who lose significant weight often need to replace clothing — a meaningful one-time or ongoing expense that GLP-1 discussions rarely include.
• Gym memberships and fitness spending. Many patients find that reduced weight makes exercise feel possible in ways it wasn't before. New memberships, classes, or equipment are common for this group.
• No change at all. Some patients experience robust appetite suppression and still maintain essentially the same spending habits — just smaller portions of the same foods.

Many patients report that their situation is more nuanced than a simple savings calculation. The point is that the common assumption that a GLP-1 is purely additive to your monthly budget deserves a second look. It may not be.

Why This Isn't Marketing Spin

The most credible thing about the data in this article is who reported it and why they had every reason not to.

Walmart is a food retailer. If GLP-1 users are buying less food, that is a problem for Walmart's revenue. Doug McMillon reporting this to Bloomberg was not a favor to pharma — it was an honest answer to an investor question. The honest answer was yes, it's affecting basket size.

Nestle restructured their product portfolio in response to GLP-1 adoption not to help GLP-1 manufacturers, but because investors demanded transparency about a business risk showing up in sales data.

Morgan Stanley has no stake in whether patients choose GLP-1s or not. Their survey was produced for institutional investors who needed to understand the downstream spending implications of widespread GLP-1 adoption — not because it was flattering to telehealth companies.

When the people who stand to lose from a trend admit the trend is real, that is the strongest possible evidence the trend is real. And the trend these three sources are describing is consistent: on a population level, patients on GLP-1s are spending less on food, snacks, and alcohol.

Compounded GLP-1 medications at $147–$220/month are the accessible version of this category. You do not need brand-name Ozempic pricing to participate in the same physiological response these patients are experiencing. The active ingredient class is the same — a GLP-1 receptor agonist — at a price point that doesn't require a $25 savings card with an expiration date attached to it.

What SkinnyVIP Costs — In Context

SkinnyVIP offers two compounded GLP-1 options with flat, transparent pricing — no insurance required, no membership, no contract:

• Compounded semaglutide: $147/month (3-month plan) or $220/month (month-to-month)
• Compounded tirzepatide: $198/month (3-month plan) or $250/month (month-to-month)

No membership. No contract. No auto-billing. No hidden fees. The price you see on the pricing page is what you pay — every month, regardless of what happens to your insurance, your employer, or a manufacturer's savings program.

Consumer behavior data tracked by Numerator and Circana on GLP-1 households confirms what Walmart and Morgan Stanley observed: at the household level, GLP-1 adoption correlates with measurable shifts in grocery purchasing patterns — third-party tracking data, not a pharma company's press release.

The Bottom Line

Three takeaways:

1. The corporate data shows a consistent pattern. Walmart's purchase records, Nestle's earnings commentary, Morgan Stanley's investor research, and third-party consumer tracking all point the same direction: on a population level, patients on GLP-1 medications spend measurably less on food and alcohol. That's a business problem for the world's largest food companies — not a claim from a telehealth practice.
2. Your results may vary — significantly. The population-level trend does not predict your individual experience. Some patients watch grocery and restaurant spending drop noticeably within weeks. Others feel subtle effects and see no meaningful change. Individual results vary. This is not financial advice.
3. The assumption that a GLP-1 is purely additive to your budget deserves a second look. If the medication may reduce your food and beverage spending by $100–$150/month, the net cost may be substantially lower than the sticker price. That's worth factoring in before deciding a GLP-1 is unaffordable.

Talk to your physician about whether a GLP-1 is appropriate for your health situation. If you're ready to explore compounded GLP-1 options with transparent pricing and no surprises, SkinnyVIP is here.

Sources:
1. Walmart CEO Doug McMillon, Bloomberg, October 2023: bloomberg.com/news/articles/2023-10-04/walmart-sees-customers-eating-less-as-glp-1-drugs-curb-appetite
2. Morgan Stanley GLP-1 Consumer Spending Survey, 2023: morganstanley.com/ideas/glp1-weight-loss-drug-market
3. Reuters — Nestle CEO on GLP-1 impact, February 2024: reuters.com/business/healthcare-pharmaceuticals/nestle-weight-loss-drugs-2024-02-22/
4. JAMA Psychiatry — GLP-1s and alcohol cravings, 2024: jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811
5. Numerator/Circana — GLP-1 household grocery purchase tracking: numerator.com/resources/blog/glp-1-household-grocery-purchases
6. Bureau of Labor Statistics — Consumer Expenditure Survey: bls.gov/cex/